The next focusIR Investor Webinar takes places on 14th May with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Notification of PDMR Dealing

13 Aug 2020 07:00

RNS Number : 9821V
Mereo BioPharma Group plc
13 August 2020
 

Mereo BioPharma Group plc

 

Notification of PDMR Dealing

 

London and Redwood City, Calif., August 13, 2020 - Mereo BioPharma Group plc (NASDAQ: MREO, AIM: MPH), "Mereo" or "the Company", a clinical-stage biopharmaceutical company focused on oncology and rare diseases, received notification that on August 12, 2020 John Lewicki, Chief Scientific Officer of Mereo, was granted options over 100,000 American Depositary Shares (ADSs) under the Mereo BioPharma Group plc 2019 equity incentive plan for no consideration. The exercise price for these options is USD 2.77 per ADS.

 

Option grants were also made to other Company personnel over a further 100,000 ADSs at the same exercise price.

 

This announcement and the notification below is made in accordance with the EU Market Abuse Regulation. The PDMR disclosure form required under the EU Market Abuse Regulation follows.

 

1

Details of the person discharging managerial responsibilities

a)

Name

John Lewicki

2

Reason for the notification

a)

Position/status

Chief Scientific Officer

b)

Initial notification/ Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Mereo BioPharma Group plc

b)

LEI

213800U8JQHIJOS5AS09

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument and identification code

AMERICAN DEPOSITARY SHARE (ADS) EACH REPRESENTING 5 MEREO BIOPHARMA GROUP PLC ORDINARY SHARES OF £0.003 EACH

b)

Nature of the transaction

GRANT OF AN OPTION (FOR NO CONSIDERATION) UNDER THE MEREO BIOPHARMA GROUP PLC 2019 EQUITY INCENTIVE PLAN. THE EXERCISE PRICE IS US$2.77 PER ADS (FAIR MARKET VALUE AT GRANT)

c)

Price(s) and volume(s)

 

Price(s)

Volume(s)

No consideration

100,000

 

 

d)

Aggregated information: volume, Price

e)

Date of the transaction

12-08-2020

f)

Place of the transaction

OUTSIDE OF A TRADING VENUE

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
DSHGZGMRGZDGGZZ

Related Shares

Back to RNS

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.